Poster 5597: In Vitro Combination Screening of IO and Targeted Agents

Genomic Profiling of Syngeneic Mouse Cell Lines and Model In Vitro Screen Against Checkpoint Inhibitors and Targeted Agents for Preclinical Applications

Frank Xing, Xiaoxi Xu, Chunlan Dong, Wubin Qian, Huajun Yang, Zhengzheng Bao, Songling Zhang, Meng Qiao, Sheng Guo, and Qian Shi

CrownBio has developed a syngeneic model screening platform to facilitate the preclinical efficacy testing of immuno-oncology agents in vivo (MuScreen™, Poster 1665).

To combine the separate therapeutic strategies of activating immune cells against a tumor, and targeting the unique genetic characteristics of a cancer model, syngeneic mutation, expression, and drug response profiles need to be characterized.

This can provide a preclinical platform for the in vitro assessment of the combinatory effects of targeting both the immune system and specific oncogenic targets.

Read this Poster to Discover:

• The development of a fast and cost-efficient in vitro platform to assess checkpoint inhibitor immune response, alone and in combination with targeted agents
  
  
• Initial correlation between genomic and pharmacological data
  
  
• Expansion plans for our in vitro syngeneic mouse cell line panel, to provide informative suggestions toward in vivo MuScreen studies

Download the Poster Now!